Patents Assigned to Bloodworks
-
Patent number: 12030956Abstract: Compositions and methods of using antibodies that are able to recognize single amino acid polymorphisms in a protein are provided. Compositions are disclosed which may be used for blood typing or to block hemolytic transfusion reactions and/or hemolytic disease of the fetus and newborn.Type: GrantFiled: January 7, 2022Date of Patent: July 9, 2024Assignee: Bloodworks NWInventor: James Charles Zimring
-
Patent number: 11892458Abstract: Compositions and methods for determining post-transfusion survival or toxicity of red blood cells and the suitability of red blood cell units for transfusion by measuring the levels of one or more compounds in a red blood cell sample are provided.Type: GrantFiled: November 9, 2020Date of Patent: February 6, 2024Assignee: Bloodworks NWInventor: James Charles Zimring
-
Patent number: 11693018Abstract: Methods for testing a red blood cell (RBC) unit for release for transfusion into a subject are described. The methods allow management of the blood supply by assessing the viability of an RBC unit by its levels of dicarboxylic fatty acids (DFA). The methods include testing an RBC sample from an RBC unit for levels of DFA and discarding the RBC unit or releasing or not releasing the RBC unit for transfusion based on the results.Type: GrantFiled: October 26, 2020Date of Patent: July 4, 2023Assignee: Bloodworks NWInventor: James Charles Zimring
-
Patent number: 11397183Abstract: The instant disclosure provides biomarkers and methods for identifying subjects at risk of developing cytokine release syndrome (CRS), neurotoxicity, or both after adoptive immunotherapy to guide preemptive intervention, modified therapy, or the like. For example, adverse event biomarkers may be measured in a subject before pre-conditioning chemotherapy, before immunotherapy (e.g., adoptive immunotherapy infusion comprising a chimeric antigen receptor (CAR) modified T cell), or shortly after pre-conditioning chemotherapy and/or immunotherapy. Exemplary biomarkers include temperature, cytokine levels and endothelial activation biomarkers, such as angiopoietin 2, von Willebrand factor (vWF), ratio of angiopoietin 2 to angiopoietin 1, and ratio of ADAMTS13 to vWF. Also provided are methods of treating subjects identified as at risk of developing cytokine release syndrome (CRS), neurotoxicity, or both to minimize such potential adverse events.Type: GrantFiled: February 9, 2018Date of Patent: July 26, 2022Assignees: Fred Hutchinson Cancer Center, University of Washington, Bloodworks NorthwestInventors: W. Conrad Liles, Cameron J. Turtle, David G. Maloney, Stanley R. Riddell, Mark M. Wurfel, Jose Lopez, Dominic Chung, Junmei Chen
-
Publication number: 20220204645Abstract: Compositions and methods of using antibodies that are able to recognize single amino acid polymorphisms in a protein are provided. Compositions are disclosed which may be used for blood typing or to block hemolytic transfusion reactions and/or hemolytic disease of the fetus and newborn.Type: ApplicationFiled: January 7, 2022Publication date: June 30, 2022Applicant: BloodworksInventor: James Charles Zimring
-
Patent number: 11248060Abstract: Compositions and methods of using antibodies that are able to recognize single amino acid polymorphisms in a protein are provided. Compositions are disclosed which may be used for blood typing or to block hemolytic transfusion reactions and/or hemolytic disease of the fetus and newborn.Type: GrantFiled: February 28, 2019Date of Patent: February 15, 2022Assignee: BloodworksInventor: James Charles Zimring
-
Patent number: 11181534Abstract: Compositions and methods useful for point of care testing for hemophilia by measuring coagulation factor levels are provided.Type: GrantFiled: April 6, 2015Date of Patent: November 23, 2021Assignee: BloodworksInventors: Jill Marie Johnsen, Barbara A. Konkle
-
Publication number: 20210356479Abstract: Compositions and methods which are useful for determining the sensitivity and specificity of antibody detection reagents are disclosed.Type: ApplicationFiled: June 25, 2021Publication date: November 18, 2021Applicant: BloodworksInventor: James Charles Zimring
-
Patent number: 11105820Abstract: Photonic devices, systems, and methods for detecting an analyte in a biological solution (e.g., whole blood) are provided. Representative photonic devices are optical ring resonators having nanoscale features and micron-sized diameters. Due to the compact size of these devices, many resonators can be disposed on a single substrate and tested simultaneously as a sample is passed over the devices. Typical analytes include blood cells, antibodies, and pathogens, as well as compounds indicative of the presence of blood cells or pathogens (e.g., serology). In certain embodiments, blood type can be determined through photonic sensing using a combination of direct detection of blood cells and serology. By combining the detection signals of multiple devices, the type of blood can be determined.Type: GrantFiled: September 11, 2020Date of Patent: August 31, 2021Assignees: University of Washington through its Center for Commercialization, BloodworksInventors: Daniel M. Ratner, Jill M. Johnsen, James T. Kirk, José A. López, Norman D. Brault, Shaoyi Jiang
-
Patent number: 11085937Abstract: Compositions and methods which are useful for determining the sensitivity and specificity of antibody detection reagents are disclosed.Type: GrantFiled: September 23, 2016Date of Patent: August 10, 2021Assignee: BloodworksInventor: James Charles Zimring
-
Patent number: 11047868Abstract: Compositions and methods for determining post-transfusion survival or toxicity of red blood cells and the suitability of red blood cell units for transfusion by measuring the levels of one or more markers in a red blood cell sample are provided.Type: GrantFiled: January 23, 2020Date of Patent: June 29, 2021Assignee: BloodworksInventor: James Charles Zimring
-
Publication number: 20210088535Abstract: Photonic devices, systems, and methods for detecting an analyte in a biological solution (e.g., whole blood) are provided. Representative photonic devices are optical ring resonators having nanoscale features and micron-sized diameters. Due to the compact size of these devices, many resonators can be disposed on a single substrate and tested simultaneously as a sample is passed over the devices. Typical analytes include blood cells, antibodies, and pathogens, as well as compounds indicative of the presence of blood cells or pathogens (e.g., serology). In certain embodiments, blood type can be determined through photonic sensing using a combination of direct detection of blood cells and serology. By combining the detection signals of multiple devices, the type of blood can be determined.Type: ApplicationFiled: September 28, 2020Publication date: March 25, 2021Applicants: University of Washington through its Center for Commercialization, BloodworksInventors: Daniel M. Ratner, Jill M. Johnsen, James T. Kirk, José A. López, Norman D. Brault, Shaoyi Jiang
-
Publication number: 20200408785Abstract: Photonic devices, systems, and methods for detecting an analyte in a biological solution (e.g., whole blood) are provided. Representative photonic devices are optical ring resonators having nanoscale features and micron-sized diameters. Due to the compact size of these devices, many resonators can be disposed on a single substrate and tested simultaneously as a sample is passed over the devices. Typical analytes include blood cells, antibodies, and pathogens, as well as compounds indicative of the presence of blood cells or pathogens (e.g., serology). In certain embodiments, blood type can be determined through photonic sensing using a combination of direct detection of blood cells and serology. By combining the detection signals of multiple devices, the type of blood can be determined.Type: ApplicationFiled: September 11, 2020Publication date: December 31, 2020Applicants: University of Washington through its Center for Commercialization, BloodworksInventors: Daniel M. Ratner, Jill M. Johnsen, James T. Kirk, José A. López, Norman D. Brault, Shaoyi Jiang
-
Patent number: 10830777Abstract: Compositions and methods for determining post-transfusion survival or toxicity of red blood cells and the suitability of red blood cell units for transfusion by measuring the levels of one or more compounds in a red blood cell sample are provided.Type: GrantFiled: September 15, 2016Date of Patent: November 10, 2020Assignee: BloodworksInventor: James Charles Zimring
-
Patent number: 10816557Abstract: Methods for testing a red blood cell (RBC) unit for release for transfusion into a subject are described. The methods allow management of the blood supply by assessing the viability of an RBC unit by its levels of dicarboxylic fatty acids (DFA). The methods include testing an RBC sample from an RBC unit for levels of DFA and discarding the RBC unit or releasing the RBC unit for transfusion based on the results.Type: GrantFiled: August 10, 2015Date of Patent: October 27, 2020Assignee: BloodworksInventor: James Charles Zimring
-
Patent number: 10785967Abstract: Provided is a transgenic mouse with modified glucose-6-phosphate dehydrogenase which can be used as a model and screening tool for various aspects of glucose-6-phosphate dehydrogenase deficiency.Type: GrantFiled: June 1, 2016Date of Patent: September 29, 2020Assignee: BloodworksInventor: James Charles Zimring
-
Patent number: 10786653Abstract: A catheter assembly with segmented or step-wise deployment stabilization system includes a base or handle, puncture needle extending from the handle, and a deployment mechanism or mechanisms to selectively extend from the distal end of the needle for first length a hollow stabilizing component and as a second step to a second further length a stabilizing guide wire element. The needle will gain sub-dermal access to the patient to the intended position for deployment of a catheter. Hollow stabilizing component provides for a first additional guide and support for a catheter sheath from the distal end of the needle. The stabilizing wire element provides additional length, guide and support for the catheter sheath. The hollow stabilizing component has some degree of flexibility as does the guide wire to minimize chance of damage to surrounding tissue.Type: GrantFiled: April 4, 2014Date of Patent: September 29, 2020Assignee: Bloodworks LLCInventors: Joshua J. Galgano, Hanjun Kim, Jr., Robert J. Anderson
-
Patent number: 10705093Abstract: Compositions and methods for determining the level of thiol and disulfide containing molecules in a sample are provided. The compositions and methods can be used to determine the level of oxidative stress in a subject with or without antioxidant treatment. Also provided are biomarkers of oxidative stress.Type: GrantFiled: July 27, 2015Date of Patent: July 7, 2020Assignee: BloodworksInventors: Xiaoyun Fu, Shelby A. Cate, Jose Aron Lopez, Junmei Chen, Barbara A. Konkle
-
Patent number: 10677781Abstract: Compositions and methods for determining post-transfusion survival or toxicity of red blood cells and the suitability of red blood cell units for transfusion by measuring the levels of one or more markers in a red blood cell sample are provided.Type: GrantFiled: March 21, 2019Date of Patent: June 9, 2020Assignee: BloodworksInventors: James Charles Zimring, Karen S. de Wolski
-
Publication number: 20200158740Abstract: Compositions and methods for determining post-transfusion survival or toxicity of red blood cells and the suitability of red blood cell units for transfusion by measuring the levels of one or more markers in a red blood cell sample are provided.Type: ApplicationFiled: January 23, 2020Publication date: May 21, 2020Applicant: BloodworksInventor: James Charles Zimring